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Abstract 
The muscular dystrophy x-linked (mdx) mouse is commonly used as a mouse model of 
Duchenne muscular dystrophy (DMD). Its phenotype is, however, mild and other mouse 
models have been explored. The mdx:cmah-/- mouse carries a human-like mutation in the 
Cmah gene and has a severe muscle phenotype, but its growth and bone development are 
unknown. In this study we compared male mdx, mdx:utrn+/-, mdx:cmah-/- and wild-type (WT) 
mice at 3, 5 and 7 weeks of age to determine the suitability of the mdx:cmah-/- mouse as a 
model for assessing growth and skeletal development in DMD.   
Mdx:cmah-/- mice were lighter than WT mice at 3, but heavier at 7 weeks (p=0.02) and showed 
an increased growth rate at 5 weeks (p=0.007). Cortical bone fraction as assessed by micro-
computed tomography was greater in both mdx and mdx:cmah-/-  mice v WT mice at 7 weeks 
(p<0.05).Tissue mineral density was also higher in mdx:cmah-/-  mice at 3 (p<0.05) and 7 
(p<0.01) weeks. Gene profiling of mdx:cmah-/-  bone identified increased expression of Igf1, 
Igf1r and Vegfa. Both the mdx and mdx:cmah-/-  mice showed an increased proportion of 
regulated bone marrow adipose tissue  (BMAT) but a reduction in constitutive BMAT. 
The mdx:cmah-/-mice show evidence of catch-up growth and more rapid bone development. 
This pattern does not mimic the typical DMD growth trajectory and therefore the utility of 
the mdx:cmah-/-  mouse for studying growth and skeletal development in DMD is limited. 
Further studies of this model may however shed light on the phenomenon of catch-up 
growth.   
 
Keywords 
Duchenne muscular dystrophy, Growth, Skeletal development, Marrow adiposity, Micro CT 
Growth plate 
 
Summary statement 
Unlike boys with DMD, the mdx:cmah-/-  mouse shows evidence of increased weight gain 
and more rapid bone development and therefore its utility for studying growth and skeletal 
development in DMD is limited. 
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 Introduction 
Duchenne muscular dystrophy (DMD) affects 1 in 4000 live male births and is a severe and 
ultimately fatal X-linked recessive disease (Emery 1991). Although progression of DMD can be 
slowed with the administration of glucocorticoids (GC), therapy is often associated with 
growth retardation and skeletal fragility (Biggar et al. 2006, Joseph et al. 2019). However, it is 
clear that growth impairment and fractures are also prevalent in steroid-naïve boys with DMD 
(Rapaport et al. 1991, Larson and Henderson 2000, Matsumoto et al. 2017), suggesting that 
there may be an intrinsic abnormality of growth and skeletal development in DMD (Eiholzer 
et al. 1988). Specifically, an older retrospective study that was carried out before GC became 
standard of care found that 44% of steroid-naïve DMD boys had sustained a fracture (Larson 
and Henderson 2000). A more recent in vivo and clinical study has also suggested that an 
abnormality of osteoblast function may exist in bones of DMD patients (Rufo et al. 2011). To 
improve our understanding of the underlying defect in growth and skeletal development in 
DMD, there is a critical need to identify an animal model that closely mimics these clinical 
features of DMD. 
 
The muscular dystrophy x-linked (mdx) mouse is the most commonly used and best-
characterised animal model of DMD but it has limited applicability in humans, as the muscle 
phenotype is much less severe (Bulfield et al. 1984, Muntoni et al. 1993). Acute muscle 
necrosis by 3 weeks of age is followed by subsequent muscle regeneration and the overall life 
span of the mdx mouse is nearly normal (Chamberlain et al. 2007). In contrast to the relentless 
decline in muscle function in humans, the muscle force of mdx limb muscles is near-normal 
until the mice become aged (Lynch et al. 2001, Muller et al. 2001). The utrophin heterozygous 
mdx mouse (mdx:utrn+/-) may represent an intermediate model between the extreme 
mdx:utrn double knockout mouse (mdx:utrn-/-), which rarely survives beyond 20 weeks of age 
(Gao et al. 2019), and the more mildly affected mdx mouse. Utrophin is an autosomal 
homologue of  dystrophin and its upregulation in the mdx mouse may compensate for the 
lack of dystrophin, thereby accounting for the less-severe phenotype compared to DMD in 
humans (Grady et al. 1997). However, the growth and skeletal development of the mdx:utrn+/- 
mouse has not previously been studied in detail. An alternative murine model of DMD is the 
mdx:cmah-/- mouse. This carries a human-like mutation in the cytidine monophospho-N-
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 acetylneuraminic acid hydroxylase (Cmah) gene that prevents synthesis of the sialic acid, N-
glycolylneuraminic acid (Chou et al. 1998, Chandrasekharan et al. 2010). The mdx:cmah-/- 
mouse has been reported to have phenotypic and molecular similarities to human DMD and 
also displays increased disease severity and reduced lifespan compared to the mdx mouse 
(Chandrasekharan et al. 2010). The mdx:cmah-/- mouse may therefore be a more appropriate 
murine model for DMD, but its growth and skeletal phenotypes have not yet been 
characterised.  
Bone marrow adipose tissue (BMAT) has attracted recent interest as a further biomarker of 
bone integrity and fracture risk, with increased BMAT often coinciding with decreased bone 
mass and increased skeletal fragility (Scheller et al. 2016). BMAT can be classified into two 
broad subtypes, regulated (rBMAT) and constitutive (cBMAT), with the former typically 
showing greater increases in conditions of bone fragility (Scheller et al. 2016). There is also 
evidence to show that muscle disuse is associated with an increase in BMAT (Gorgey et al. 
2013). However, the impact of DMD on BMAT has not been assessed previously.    
The aim of this study was to further establish and compare the bone structure and function, 
BMAT quantity and growth phenotypes of the mdx, mdx:utrn+/- and mdx:cmah-/- DMD mouse 
models with the C57BL10 WT mouse and determine which model would most closely mimic 
the clinical characteristics of DMD.  
 
We hypothesised that growth and growth plate (GP)  chondrogenesis and bone 
development are impaired in the muscular dystrophy mouse models when compared to WT 
mice and more severely in the mdx:cmah-/- mouse model. In addition, rBMAT, but not 
cBMAT, would be inversely associated with bone loss in each model. Accurate 
characterisation of the bone and growth would enable choice of an appropriate animal 
model when testing new therapies.   
 
Results 
Grip strength and inflammation in muscular dystrophy models 
Histology of the tibialis anterior muscle revealed areas of necrosis with a significant increase 
in percentage of inflammatory cells within all the muscular dystrophy models at 3 weeks of 
age (Fig. 1A).  There was evidence of muscle fibre necrosis and regeneration with an increase 
in centrally located myonuclei and fibre size variation by 5 and 7 weeks of age, which was 
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 particularly noticeable in the mdx and mdx:utrn+/- mice (Fig. 1B ii,iii). This is compared to WT 
mice whose muscle histology showed normal, regular myofibres with peripheral nuclei and 
intact sarcoplasm at all ages studied, with minimal evidence of inflammation or regeneration 
(Fig. 1Ai, Bi, C).  Grip strength (normalised to bodyweight) was less in all muscular dystrophy 
models at 3 weeks of age compared to WT mice (p<0.01) (Fig. 1D). Reduced grip strength was 
also noted in all muscular dystrophy models at 5 and 7 weeks of age but the changes did not 
always reach significance (Fig. 1D). Serum CK activity was >10-fold higher in all muscular 
dystrophy mice and at all ages compared to WT mice, providing further evidence for muscle 
damage in these muscular dystrophy models (Fig.1E).  
 
Anthropometric measurements 
Body weight and body length were measured from weaning (3 weeks of age) (Table 1). No 
differences were observed in the body weight of the mdx or mdx:utrn+/- mice compared to 
WT at any time-point. In contrast, mdx:cmah-/- mice were almost 2 g lighter than WT mice at 
3 weeks of age (8.07 g vs 10.03 g, p=0.02), but were 3 g heavier by 7 weeks of age (21.97 g vs 
24.97 g, p=0.02). Consistent with this, when analysing the mice that were culled at 5 or 7 
weeks of age (i.e. those with longitudinal growth data available), the mdx:cmah-/- mice gained 
significantly more weight than WT mice from 3-5 weeks of age (8.77 g vs 10.61 g, p=0.01). 
Weight gain slowed between 5 and 7 weeks of age in all models and there were no genotype 
differences in weight gain during this period (Fig. 1F). When genotype and age were 
incorporated into a multivariable linear regression model, mdx:cmah-/- mice were associated 
with an increased growth rate (co-eff 1.84, p<0.05) during the overall study period. No 
differences in bodyweight were observed in the mdx or mdx:utrn+/- mice compared to WT 
mice at any time-point studied. 
 
Tibia length, growth rate and growth plate analysis 
Tibia length from similarly aged WT and muscular dystrophy mice was comparable, as was 
the rate of longitudinal bone growth (assessed by calcein labelling); one exception was for 
mdx:cmah-/- mice, which had an increased growth rate at 5 weeks of age (p=0.05) (Fig. 2).  
When genotype and age at cull were incorporated into a multivariable linear regression 
model, mdx:cmah-/- mice were associated with an increased overall longitudinal bone growth 
rate within the GP (co-eff 18.6, p<0.01) compared with WT and the other muscular dystrophy 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 mouse models.  Closer examination of the proximal tibial GP of 3- and 7-week-old muscular 
dystrophy mice also revealed no changes in total GP width or the width of the proliferative 
and hypertrophic zones (Suppl Fig. 1). Similarly, chondrocyte proliferation was unaffected in 
any of the muscular dystrophy mice at 3 weeks of age (Suppl Fig. 1).  We attempted to assess 
the number of apoptotic hypertrophic chondrocytes in 7-week-old mice, but the numbers of 
these cells were too sparse to enable accurate quantification (data not shown).  
 
Bone phenotype in the muscular dystrophy models 
Very few structural changes were observed in the cortical bone of the muscular dystrophy 
mice compared to WT mice (Table 2, Supplementary Table 1, Fig. 3A). Cortical bone area and 
cortical bone fraction were lower in mdx:cmah-/- mice compared to WT mice at 3 weeks of 
age (p<0.05). However, in all 7-week-old muscular dystrophy models a higher cortical bone 
fraction was noted compared to WT mice (p<0.05) (Fig. 3B). Cortical tissue mineral density 
was higher in mdx:cmah-/- mice at 3 (p<0.05) and 7 (p<0.01) weeks of age and in mdx:utrn+/- 
mice at 5 weeks (p<0.01) when compared to WT mice (Fig. 3C).  Trabecular tissue architecture 
was also relatively unchanged in the various muscular dystrophy models (Table 2, 
Supplementary Table 2, Fig. 3A). The most stark difference was in trabecular tissue volume, 
which was lower in mdx:cmah-/-mice at all ages studied and this reached significance at 3 and 
7 weeks of age (p<0.001), (Fig. 3D).  Also, there was a trend for lower trabecular connectivity 
in all muscular dystrophy mice and this reached significance in the mdx:utrn+/- mice at 5 weeks 
(p<0.05) and mdx:cmah-/- mice at both 5 and 7 weeks (p<0.01) when compared to WT mice 
(Fig. 3E).  The lack of a major bone phenotype was reflected by the normal number of 
osteoblasts and osteoclasts present on trabecular bone surfaces of the muscular dystrophy 
models (Fig. 3F,G). Serum markers of bone formation and resorption were also relatively 
normal in muscular dystrophy mice, although CTX concentrations were significantly higher 
in 3-5 week-old mdx:cmah-/- mice (406.36 ± 46.51pg/ml) compared to WT controls (181.70 ± 
78.51pg/ml), (p<0.01).   
 
Biomechanical properties  
Consistent with the small structural changes observed in the trabecular and cortical 
compartments, there were limited differences in the biomechanical properties of bones from 
WT and muscular dystrophy mice.  The only exception was a trend for lower deflection at 
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 maximum load in mdx:cmah-/- mice at all ages studied, and this difference was significant in 
mice at 5 weeks of age (Table 3).  
 
Gene and protein expression studies 
To identify more subtle changes in diaphyseal bone from muscular dystrophy mice we next 
used a PCR array to profile the expression of 84 genes involved in skeletal development 
and/or bone mineral metabolism.  This analysis was limited to bone from 7 week-old-mice 
and revealed a 2-to-3.75-fold up-regulation of matrix metalloprotease 10 (Mmp-10) and bone 
morphogenetic protein receptor type 1b (Bmpr1b) in all muscular dystrophy models 
compared to WT mice (Table 4). In mdx:cmah-/- mice, there was also increased expression of 
growth and transcription factors compared to WT control mice. In particular, there was 
increased expression of Igf-1 (30-fold), Igf1R (10-fold) and vascular endothelial growth factor 
A (Vegfa; 32-fold) (Table 4).   
Selected genes from this array were validated by IHC to confirm the presence of IGF-1, 
BMPR1b and MMP-10 proteins in tibial sections from WT and muscular dystrophy mice. 
MMP-10 and BMPR1b were chosen as they were up-regulated in all muscular dystrophy 
mouse models. IGF-1 was chosen because it is an essential factor in the regulation of post-
natal growth and showed a marked up-regulation in the bone of mdx:cmah-/- compared to 
WT mice. We were unable to detect robust, positive staining for BMPR1b (data not shown). 
In contrast, MMP-10 immunolocalisation was successful, but was similar in all sections 
examined and no genotype-specific differences in staining distribution or intensity were 
noted (data not shown).  IHC revealed greater IGF-1 staining of GP chondrocytes and cells 
associated with trabecular bone within the metaphysis (Fig.4 A-C). When quantified, IGF-1 
staining intensity was significantly greater in sections of mdx:cmah-/- mice compared to WT 
mice (Fig. 4D). 
 
Bone marrow adipose tissue (BMAT) quantification in tibiae 
The proportion of total BMAT within the tibial marrow cavity of WT and muscular dystrophy 
mice was similar. However, in comparison to WT mice, % rBMAT was higher in both mdx and 
mdx:cmah-/- mice whereas % cBMAT was lower in both muscular dystrophy models (Fig.  5). 
Although the BMAT of mdx:utrn+/- mice was not studied, these observations suggest that 
BMAT volume and distribution may be altered in DMD. 
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 Metatarsal culture 
To determine if there was an intrinsic skeletal insult in these muscular dystrophy models, we 
also investigated the growth potential of bones from WT, mdx and mdx:cmah-/- mice in an ex 
vivo organ culture model.  Over a 7-day period the growth of metatarsals from muscular 
dystrophy and WT mice was similar (Suppl Fig 1D). 
 
Discussion  
We have demonstrated a significant muscle phenotype in all three muscular dystrophy 
models and also confirmed age and strain-related characteristics. Consistent with published 
data, the mdx:cmah-/- mice exhibited a marked muscle phenotype (Chandrasekharan et al. 
2010). This is consistent with the theory that lower levels and function of the dystrophin-
glycoprotein complex and metabolic accumulation of dietary N-glycolyneuraminic acid, which 
occur as a consequence of the cmah mutation, contribute to a more-severe muscle 
phenotype. Indeed, our analyses of muscle histology and serum CK further demonstrate that 
the mdx mice have a greater capacity for muscle regeneration than the mdx:utrn+/- or 
mdx:cmah-/- models. In keeping with this, normalised grip strength was significantly lower in 
mdx compared to WT at 3 weeks of age, but not beyond this timepoint. This is consistent with 
published data on the mdx mouse suggesting that there is an early period, between the end 
of the second and up to the fifth week of life, when the mice experience histological necrosis 
and functional weakness. After this critical period, regeneration occurs and there are no co-
existing clinical features of DMD such as scoliosis and heart failure until mice are at least 15 
months or older (Bulfield et al. 1984, Muntoni et al. 1993, Lefaucheur and Sebille 1995, 
Chamberlain et al. 2007, Coley et al. 2016).  Like all the muscular dystrophy models that we 
tested, serum CK activity is significantly higher in mdx:utrn+/- mice than WT mice and muscle 
histology also demonstrated ongoing inflammation and regeneration at 5 and 7 weeks of age. 
However, the normalised grip strength was lower than WT mice only at 3 weeks of age.  Other 
studies have also reported a variable muscle phenotype (Huang et al. 2011, Mcdonald et al. 
2015).  
 
Our study is the first to describe the growth and bone phenotypes of the mdx:cmah-/- and 
mdx:utrn+/- mouse.  It was expected that there would be a growth phenotype in all the 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 muscular dystrophy models and that it would be most severe in the mdx:cmah-/- mice. 
However, our results do not support this and despite the marked muscle phenotype we find 
no evidence of a more severe skeletal phenotype in mice of up to 7 weeks-of-age. 
Unexpectedly, despite being bred in exactly the same conditions and during the same season, 
the mdx:cmah-/- mice are smaller than the WT mice at 3 weeks of age, but demonstrated 
increased weight gain such that by 7 weeks of age, they are heavier than WT mice. The smaller 
absolute bodyweight in the youngest mdx:cmah-/- mice may be a reflection of several factors, 
including poorer general health in the mothers prior to or during pregnancy or a problem pre- 
or peri-weaning in the offspring. Consistent with this, the mdx:cmah-/- mice were much harder 
to breed than expected and there were a higher than expected number of pre-wean deaths.  
The catch-up growth is suggested by gross body weight measures but also at the GP level 
through dynamic histomorphometry using calcein labelling. Additional evidence for the catch-
up growth is found in the upregulation of many growth factors on the PCR array, including a 
30-fold increase in Igf1 expression and 60-fold increase in Vegfa expression. Further evidence 
of increased bone turnover in the young mdx:cmah-/- mice compared to WT mice is suggested 
by the higher levels of -CTX, a marker of bone resorption. Although the bone formation 
marker, P1NP, was not raised at this age, it is possible that it may have risen subsequently.  
We did not find any evidence of growth retardation in either the mdx or mdx:utrn+/- mice 
compared to WT mice at any age. Consistent with our data showing no difference in tibial 
length, Romero-Nakagaki showed no significant difference in femur length between the mdx 
and WT mice at 3 week of age (Nakagaki et al. 2011).  
 
There are conflicting data regarding the bone phenotype in the mdx mouse and, unlike in 
patients with DMD, where bone strength decreases with advancing age, the converse appears 
true in some studies of mdx mice (Anderson et al. 1993). Osteopenia has also been 
demonstrated in young mdx mice (Anderson et al. 1993, Nakagaki et al. 2011, Novotny et al. 
2011).  By contrast, other studies have shown either no difference in any CT parameters 
between young mdx and WT males, or a paradoxical increase in femoral BMD on DXA in older 
female mdx mice compared to WT mice (Montgomery et al. 2005, Isaac et al. 2013) We have 
shown a higher cortical bone fraction in the mdx mice compared to WT mice, but only at 7 
weeks of age and no difference in any other parameters on CT, bone turnover markers or 
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 on biomechanical testing. This may reflect the muscle-bone crosstalk and the potential for an 
adaptive bone response alongside the muscle regeneration in the mdx model. 
Compared to the mdx mouse the data reporting on the bone structure of mdx:utrn+/- mice is 
restricted to collagen content of the metaphyseal bone, which is less in mdx:utrn+/- mice 
compared to mdx and WT mice (Isaac et al. 2013).  This present study also shows no 
conclusive evidence of altered bone structure in mdx:utrn+/- mice. Our CT data show, 
paradoxically, that TMD is higher in the mdx:utrn+/- mice compared to WT mice at 5 weeks of 
age only, while cortical bone fraction is also greater than WT mice, but only in those culled at 
7 weeks.  
 
Although we hypothesised that the mdx:cmah-/- mice would have osteoporosis, their TMD is 
increased compared to WT mice at both 3 and 7 weeks of age and cortical bone fraction is 
also higher at 7 weeks of age. This may be due to a compensatory bone response to muscle 
damage and then regeneration as described for mdx mice, but there may also be other factors 
responsible. For example, one study demonstrated that the cmah gene is upregulated in adult 
human stem cells, of both haematopoietic and mesenchymal origin. Overexpression of the 
cmah gene causes accumulation of nuclear -catenin (Nystedt et al. 2009) and associated 
restriction of Wnt signalling. Therefore it is possible that the absence of the cmah gene in the 
mdx:cmah-/- mouse model may cause a reduction in nuclear -catenin expression and 
unregulated Wnt signalling and thereby promote the osteoblast lineage and bone formation 
(Westendorf et al. 2004). 
 
We found that all the muscular dystrophy models have an up-regulation of Mmp10 and 
Bmpr1b gene expression compared to WT mice. Matrix metalloproteases (MMPs) are 
members of a family of calcium-dependent proteinases that can cleave a wide range of 
extracellular proteins, including components of the extracellular matrix. MMP10 is known to 
be involved in bone growth but has also been shown to be involved in tissue repair processes 
and specifically in muscular dystrophy mouse models (Ortega et al. 2004). Increased skeletal 
muscle MMP-10 protein expression has been demonstrated in response to the damaged, 
dystrophic muscle seen in the mdx mouse (Ortega et al. 2004).  This may also explain our 
finding that Mmp10 is upregulated in bone, because the bone-muscle unit is intrinsically 
interlinked(Veilleux and Rauch 2017). Growth factors of the transforming growth factor 
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 (TGF) family, which includes bone morphogenetic proteins (BMPs), play an important role 
in skeletal development (Chen et al. 2012) and BMP signalling in particular has been shown 
to lead to the expression and activity of genes necessary for osteoblast differentiation (Song 
et al. 2009). Increased BMP signalling has also been implicated in the pathogenesis of DMD 
and recent studies have suggested an essential role of BMPs and also the type 1 receptor in 
regeneration after muscle damage(Shi et al. 2013). Thus, our findings of increased skeletal 
Bmpr1b expression in mdx, mdx:utrn+/- and mdx:cmah-/- mice are consistent with their use as 
preclinical muscular dystrophy models.  
 
Our finding of catch-up growth in the mdx:cmah-/- mice has further implications for 
understanding the putative role of cmah in other diseases. Thus, cmah-null mice have been 
proposed as one of the best to mimic the phenotype of human metabolic disorders (Kavaler 
et al. 2011, Kwon et al. 2015). We speculate that this metabolic dysregulation may relate to 
altered developmental programming in cmah-null mice. According to the Barker hypothesis 
and the developmental origins of health and disease, predisposition to the development of 
the metabolic syndrome begins in utero during critical periods of foetal development. During 
such periods, changes occur to promote foetal survival in the adverse intrauterine 
environment, but in later life these changes can also have a lasting impact on health and the 
development of the metabolic syndrome. The mdx:cmah-/- mice in this study were smaller 
than expected for the C57/BL10 background and displayed catch-up growth in keeping with 
the ‘thrifty phenotype’, but the process and the exact role of the cmah mutation remains 
unclear. One possibility is that these mice have mitochondrial dysfunction caused by oxidative 
stress, but it is unclear if this is a cause or consequence of their insulin resistance (Kwon et al. 
2015).  
 
The assessment of BMAT provided some very interesting and unexpected findings. We have 
shown that there is a significant increase in rBMAT in both the mdx and mdx:cmah-/- mice but 
a marked decrease in cBMAT. The causes and consequences of this increase, as well as its 
clinical relevance, warrant further investigation. Several mechanisms might account for the 
altered BMAT. Studies have shown that rBMAT is increased during obesity and, paradoxically, 
also during caloric restriction (Devlin 2011, Cawthorn et al. 2014), whereas loss of cBMAT is 
less common and is most pronounced in lipodystrophic conditions. This indicates modulation 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 of BMAT in states of altered systemic energy homeostasis.  The role of dystrophin in the 
regulation of metabolism is poorly understood and is difficult to evaluate clinically as body 
composition in DMD is confounded by the long-term use of high-dose GC. However, a recent 
study demonstrated that dystrophin deficiency in the mdx mouse resulted in reduced body 
fat (confirmed by DEXA body composition studies) and a consistently lower core body 
temperature, despite no overall bodyweight difference between the mdx and WT (Strakova 
et al. 2018). Similar studies have shown increases in energy expenditure and muscle protein 
synthesis in the mdx mouse and an altered response to high-fat diet compared to C57BL10 
controls (Radley-Crabb et al. 2011, 2014). The differences were found in spite of a higher level 
of food consumption. Thus, it is possible that the increase in rBMAT occurs as a response to 
altered energy homeostasis in the DMD mice. In humans, increased BMAT is associated with 
increased plasma lipids (Scheller et al. 2016); however, studies examining serum lipid levels 
have shown no difference between mdx and WT mice (Milad et al. 2017). In contrast, mdx 
mice appear to have defects in expansion of primary adipose progenitor cells in vitro (Joseph 
et al. 2018), and therefore altered BMAT may also relate to differences in adipose progenitor 
cells. 
 
The consequences of altered BMAT are also interesting to consider. Marrow adipocytes have 
been suggested to regulate skeletal remodelling, haematopoiesis and metabolic homeostasis. 
Moreover, logic dictates that accumulation of rBMAT in proximal tibia must occur at expense 
of either haematopoiesis or bone, given the finite size of the marrow cavity. Consistent with 
this, we found that trabecular bone is decreased in 7-week-old mdx:cmah-/- mice. However, 
cortical bone in each muscular dystrophy model was increased at 7 weeks of age, which is at 
odds with the increased rBMAT. It would be worth assessing haematopoiesis in these mice, 
given the potential for BMAT to modulate this process. Clinically, osteoporosis has been 
associated with a decrease in BMAT unsaturation (Yeung et al. 2005) and bone marrow fat 
composition has been suggested as a useful biomarker in post-menopausal women with 
fragility fractures (Patsch et al. 2013). Thus, altered BMAT may also have a useful prognostic 
role in DMD. Future studies should explore these possibilities. 
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 Conclusion 
In conclusion, our results confirm that all three of the DMD mouse models examined showed 
marked muscle damage and impaired grip strength as expected and consistent with the 
literature. We have also demonstrated differences in BMAT composition, which may serve as 
a potential biomarker for bone fragility in patients with DMD.  However, we find no consistent 
bone or growth defect in any of the DMD models at all ages studied. This may become 
apparent in older mice, but it is likely that, to mimic more closely the osteoporosis and growth 
retardation that are observed in boys with DMD, glucocorticoids must be given to the mice. 
In particular, we find that the mdx:cmah-/- mouse certainly does not mimic the growth 
trajectory of boys with DMD, but instead appears to display catch-up growth and increased 
bone turnover with a resultant increase in TMD and cortical bone fraction. Rather than being 
a useful murine model for growth retardation and osteoporosis in DMD, the mdx:cmah-/- 
mouse may in fact be useful when a model of catch up growth is desired.  
 
Materials and methods 
Animals and experimental procedures 
Four different mouse strains were examined: Wild-type (WT) - C57BL/10ScSnJ; mdx - 
C57BL/10ScSn.mdx; mdx:utrn - C57BL/10ScSn.utrn/mdx; and mdx:cmah-/- - B10.Cg-
CMahtm1AvrkDmdmdx/PtmJ. All mice were obtained from Jackson laboratories (Jackson, New 
Harbour, MA). All animal experiments were approved by the Roslin Institute's Animal Users 
Committee, and mice were maintained in accordance with Home Office (UK) guidelines for 
the care and use of laboratory animals.  All mice were housed under controlled temperature 
(approx. 25C) and light conditions (12h light:12h dark cycle) and offered food and water ad 
libitum. A cross-sectional study was performed whereby mice were culled at three 
developmental ages (3, 5 and 7 weeks of age). A minimum of 6 male mice of each genotype 
were used at each time point. Additional mice were used for the assessment of marrow 
adiposity. Body weight, crown-to-rump and tail length measurements were taken twice 
weekly using digital weighing scales and a ruler.  
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 Grip strength 
Forelimb grip strength testing was performed within 24 hours prior to cull, using a grip 
strength meter with a specialised mouse grid (Harvard Biosciences, Massachusetts, USA), 
according to the TREAT-NMD standard operating protocol (Luca 2014). The mean of three 
consecutive measurements was calculated and normalised to body mass. 
 
Muscle histology 
The tibialis anterior muscles were removed and fixed in 4% paraformaldehyde (PFA) before 
undergoing paraffin wax-embedding. Sections (6 µm) were stained with haematoxylin and 
eosin for histological assessment, according to the TREAT-NMD protocol (Grounds 2014). 
Images were acquired using a Zeiss AxioImager brightfield microscope and analysed using Fiji 
(Schindelin et al. 2012). The percentage of inflammatory cells in the region of interest (ROI) 
was calculated and the number of central nuclei (signifying muscle regeneration) recorded, 
to obtain a cumulative measure of skeletal muscle damage.  
 
Serum Measurements 
Immediately following euthanasia, blood was obtained from non-fasted animals via cardiac 
puncture. Serum creatine kinase (CK) concentration was measured by a CK assay kit (Pointe 
Scientific, Stroud, UK) in samples collected at 3, 5 and 7 weeks of age. Serum P1NP and CTX 
was measured by ELISA (AMS Biotechnology, Abingdon, UK) at 3 weeks of age.  
 
Micro-CT analysis  
Micro-computed tomography imaging (CT) was performed to quantify trabecular 
architecture, cortical bone geometry, tissue mineral density (TMD) and tibia length. Left tibiae 
were dissected from all mice, stored in H20 at -20°C and thawed prior to scanning with a 
SkyScan 1272 X-ray microtomograph (Bruker Corporation, Kontich, Belgium). The bones were 
wrapped in paper tissue and enclosed at a consistent vertical height in tightly fitting rigid 
plastic tubes filled with water, to prevent movement artefact. Two images were averaged at 
each rotation angle to reduce noise. For trabecular bone, images were obtained at a 4.5 m 
resolution, using a 0.5 mm aluminium filter and 0.3 rotation step. For cortical bone image 
accrual and tibial length measurements, images were obtained at a 9 m resolution using a 
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 0.5 mm aluminium filter with a 0.5 rotation step. Scans were reconstructed using NRecon 
software (Bruker) and a volume of interest was selected using Data Viewer software (Bruker). 
Two hundred slices of the metaphysis were taken for analysis of trabecular bone, with the 
ROI starting 10 slices below the base of the growth plate (GP). One hundred slices of the 
diaphysis were taken for analysis of cortical bone, with the ROI starting 50 slices above the 
tibia-fibula junction. CTAn software (Bruker) was used to analyse appropriate parameters. 
Cortical TMD was calculated using hydroxyapatite rod pair phantoms of a known density (0.25 
g/cm3 and 0.75 g/cm3), which were scanned using the same settings used for cortical image 
accrual. Tibial length was measured from the proximal tibial plateau to the distal tip of the 
medial malleolus.  
 
Bone Marrow Adiposity 
Marrow adiposity was assessed by osmium tetroxide staining of intact right tibiae of 7-week-
old mice, as previously described (Scheller et al. 2014).  Tibiae were fixed in neutral-buffered 
formalin for 1 week, scanned by CT imaging, decalcified in 14% ethylenediamineteraacetic 
acid (EDTA) for 2 weeks at 4ºC and then stained with 1% osmium tetroxide solution for 48 
hours before further CT imaging.  The volumes of total, regulated (r) and constitutive (c) 
BMAT (Ad.V) were determined and calculated as the percentage of the marrow cavity volume 
(Ma.V), which was determined by CT prior to staining. (Scheller et al. 2015). 
 
Biomechanical testing 
Three-point bending analysis of the cortical region of the left tibiae was carried out 
immediately after CT, using a Lloyd LRX5 materials testing machine (Lloyd Instruments, West 
Sussex, UK). A 100N loading cell was used with the span fixed at 10 mm and the cross-head 
lowered at 1 mm/min to determine load to failure and maximum stiffness and deflection of 
tibiae (Huesa et al. 2011). 
 
Bone histomorphometry 
Two days prior to sacrifice the mice received an intraperitoneal injection of 30 mg/kg calcein. 
After dissection, the right femur was fixed in 4% PFA for 24 hours, transferred to 70% ethanol 
and then embedded in methylmethacrylate to allow quantification of longitudinal growth 
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 rate at the chondro-osseous junction (Owen et al. 2009, Dobie et al. 2015). Right tibiae were 
de-calcified for 3 weeks in 10% EDTA and processed to wax using standard procedures. 
Sections were stained with Toluidine blue to enable calculation of total and zonal widths of 
proliferating and hypertrophic zones of the GP (Owen et al. 2009). Static histomorphometry 
was performed on paraffin-embedded, decalcified sections of tibiae from mice culled at 5 
weeks of age. Tartrate-resistant acid phosphatase (TRAP) activity and fast-red staining was 
used to identify osteoclasts (TRAP+ve) as multinucleated cells lying on the bone surface. 
Osteoblasts were visualised by their cuboidal appearance and by the presence of alkaline 
phosphatase (ALP) activity. Images from 5-week-old mice were scanned using a Nanozoomer 
slide scanner (Hamamatsu Photonics, Japan) and then the trabecular area of the proximal 
tibia were analysed. The RoI included only metaphyseal trabecular bone and extended from 
50 m below the GP and within the endocortical bone boundary. Osteoblast and osteoclast 
numbers per bone surface were determined using BioqantOsteo v 11.2.6 (Bioquant Image 
Analysis Corp, Nashville, Tennessee, USA), in accordance with the American Society of Bone 
and Mineral Research Guidelines for nomenclature (Dempster et al. 2013). 
 
Assessment of chondrocyte proliferation and apoptosis 
The ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (EMD Millipore, Bedford, MA, 
USA) was used as per manufacturer’s instructions to quantify the number of apoptotic cells 
in the tibial GP of 7-week-old mice. Proliferating cell nuclear antigen (PCNA) 
immunohistochemistry (IHC) was performed using a 1:4000 dilution of an anti-PCNA antibody 
(Abcam, Cambridge, UK) followed by the Vectastain elite ABC rabbit kit (Vector labs, 
Peterborough, UK) on paraffin-embedded sections from 3-week-old mice (when rates of 
proliferation were likely to be highest). Sections were counterstained by haematoxylin and 
viewed using a Zeiss AxioImager brightfield microscope. The haematoxylin - DAB colour 
deconvolution plugin was used on Fiji to calculate the percentage of PCNA +ve cells in the 
proliferating zone of the GP of each sample.  
 
RNA extraction and PCR array 
The epiphyses of the right humerus of 7-week-old mice were removed and the shaft 
centrifuged to remove the bone marrow. Thereafter, cortical bone shaft was snap frozen in 
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 liquid nitrogen. RNA was extracted using a modified version of the Qiagen RNeasy kit 
(Manchester, UK) and reverse transcribed using standard procedures.  The cDNA was 
analysed on the real-time RT2 profiler PCR osteogenesis pathway 84-gene array (Qiagen, 
Manchester UK), in combination with RT2 SYBR Green qPCR Mastermix (Qiagen, Manchester 
UK) in a Stratagene Mx3000P PCR cycler (Stratagene, CA, USA). Relative gene expression for 
each gene was calculated in the muscular dystrophy mouse models compared to the WT 
control group using the 2-CT method (Livak et al. 2001). CT for each sample was 
normalised using the geometric mean of the Gapdh housekeeping reference gene (included 
within the array) as this was found to be the most consistent of the 5 housekeeping genes 
included in the RT2 osteogenesis array (Gusb, Actb, B2m and Hsp90ab1 also tested) across all 
samples analysed. CT values of >35 cycles were considered non-specific and discarded.  
 
Immunohistochemistry 
A standard indirect IHC procedure was used to detect Insulin-like growth factor-1 (IGF-1), 
bone morphogenetic protein receptor 1b (BMPR1b) and matrix metalloprotease protein-10 
(MMP-10) expression (Dobie et al. 2015). Primary antibodies were IGF-1 (Abcam, 
ab9572,1:500 dilution) BMPR1b (Abcam, ab175385, 1:100 dilution) and MMP10 (Abcam, 
ab199688, 1:100 dilution).  Control sections were incubated with an equal amount of rabbit 
IgG in place of the primary antibody. Sections were counterstained by haematoxylin, 
mounted, and images captured using a Zeiss AxioImager brightfield microscope. Fixation and 
antigen retrieval were carried out using the same methodology throughout and all IHC for 
each antibody was performed on the same day under identical conditions, with control 
specimens also tested for each genotype. After the images were imported into Fiji, the 
haematoxylin-DAB colour deconvolution plugin was used to separate the haematoxylin and 
DAB components and the ‘analyse-measure’ tool used to determine the absorbance in a 
consistent region of each sample, containing both GP and metaphyseal bone. Optical density 
(OD) was then calculated using the equation: 
OD= negative (base10)log of mean intensity of transmitted image/illumination (max 
intensity of image) 
Maximum intensity was taken to be 255 for 8-bit images in Fiji (Ruifrok and Johnston 2001). 
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Metatarsal culture 
Embryonic (day 18) metatarsal culture was performed as previously described (Houston et al. 
2016). The middle three metatarsals were cultured for 10 days and the total length of the 
metatarsal was measured at day 0, 3, 5, and 7 days using a Nikon eclipse TE300 microscope 
with a digital camera attached and Image Tool software (Image Tool Version 3.00, San 
Antonio, TX). 
 
Statistical analysis 
Mice were identified only by number at the time of culling, to enable blinding by genotype. 
For clarity, the mdx:cmah-/- mice are referred to as mdx:cmah and mdx:utrn+/- mice as 
mdx:utrn. Statistical comparisons were made between mice of each genotype and age, using 
STATA v15 and GraphPad Prism v7. After checking for normality of data, one-way ANOVA was 
used to assess significance of differences between groups and post-test Bonferroni 
modifications were made to adjust for multiple comparisons. Data are presented as mean ± 
SD. A p-value of <0.05 was accepted as significant. Linear multivariable regression models 
were used when appropriate to estimate the relationship between the outcome variable 
under investigation and other independent variables, after adjustment for any potential 
confounders. Following model generation, regression diagnostics were performed to check 
the underlying assumptions of the linear model. Residual normality was checked using a 
normal probability plot and a residual versus fitted plot drawn to ensure that the variance of 
errors was constant throughout the range of residuals. CT data were also standardised for 
tibial length and bodyweight at cull, but significant results remained the same and therefore 
only unadjusted data are shown. RT-qPCR raw data was analysed using the Qiagen web-based 
PCR array data analysis tool. In accordance with this, p-values were calculated based on a 
Student’s t-test of the CT data and a fold change >1 was considered as up-regulation, and <-
1 as down-regulation.  
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Figure 1    A)  Haematoxylin and Eosin stained section of tibialis anterior from: i)   3 week- 
old WT mouse showing normal, regular myofibres with peripheral nuclei and intact 
sarcoplasm ii)  3 week-old mdx iii) 3 week-old mdx:utrn+/- iv) 3 week-old mdx:cmah-/- mouse 
showing many inflammatory cells with a barely visible sarcoplasm. B)  Haematoxylin and 
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 Eosin stained section of tibialis anterior from: i) 7 week- old WT mouse showing normal, 
regular myofibres with peripheral nuclei and intact sarcoplasm ii) 7 week-old mdx iii) 7 
week-old mdx:utrn+/- iv) 7 week-old mdx:cmah-/- showing regeneration with larger myofibres 
and central nuclei. C) Muscle cell inflammation was present in all muscular dystrophy 
models by 3 weeks of age followed by regeneration at 5 and 7 weeks of age.  D)  Mean grip 
strength by age and genotype showing a reduction in muscular dystrophy mice.  E)  Higher 
CK activity in muscular dystrophy mice at all ages.  Data is presented as mean ± SD (n > 6); 
*denotes p<0.05 ** denotes p<0.01 *** p<0.001 for cumulative measures of muscle 
damage compared to WT mice. F) Increased weight gain is seen in the young mdx:cmah-/- 
mice. i) Increased rate of weight gain in the mdx:cmah-/- mice occurred between 3 and 5 
weeks-of-age but not between 5 and 7 weeks-of-age. Data presented are mean (symbol) 
and standard deviation (whiskers). * denotes p<0.05 compared to WT mice. ii) Example of a 
growth chart for a WT mouse compared to a mdx:cmah-/- mouse showing the lower initial 
weight and the rapid growth velocity seen in the early weeks in the mdx:cmah-/- mouse. 
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Figure 2 A) Longitudinal bone growth during the study period. Data are presented as mean ± 
SD. * denotes p<0.05 compared to WT mice of the same age. B) examples of calcein- labelled 
GP in a 5-week old i) mdx:cmah-/- and ii) mdx mouse showing the increased longitudinal 
growth rate in the mdx:cmah-/- mouse (red arrows). 
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Figure 3 A) Representative Micro-CT images of tibial bone of all genotypes at 3, 5 and 7 weeks 
of age to show bone development (upper row mid diaphyseal cortical bone, lower row 
metaphyseal trabecular bone). B) Compared to similarly aged WT mice, cortical bone fraction 
was lower in mdx:cmah-/- mice at 3 weeks of age, but higher in all muscular dystrophy models 
at 7 weeks of age. C) Cortical tissue mineral density was higher in mdx:cmah-/- mice at 3 and 7 
weeks of age and in mdx:utrn+/- mice at 5 weeks when compared to WT mice.  D) Trabecular 
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 tissue volume was lower in mdx:cmah-/- mice at 3 and 7 weeks of age.  E)  Trabecular 
connectivity was lower in mdx:utrn+/- mice at 5 weeks and mdx:cmah-/- mice at both 5 and 7 
weeks when compared to WT mice.  The number of osteoblasts (F) and osteoclasts (G) were 
normal in all muscular dystrophy models at 5 weeks of age.  Data is presented as mean ± SD (n 
> 6); *denotes p<0.05 ** denotes p<0.01 *** p<0.001 compared to WT mice. 
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Figure 4 Immunolocalisation of IGF-1 in sections of A) WT and B) mdx:cmah-/- tibiae showing 
greater staining intensity in cells of both ossification centres and the growth plate. C)  Control 
section in which rabbit IgG was substituted for the primary antibody. D) Quantification of IGF-
I staining in growth plate chondrocytes and metaphysis of tibiae from WT and muscular 
dystrophy mouse models.  Data are presented as mean ± SD (n = 6) * denotes p<0.05 compared 
to WT mice. 
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Figure 5 3-dimensional CT reconstructions of 7 week-old osmium-stained tibiae from: A) WT 
B) mdx and C) mdx:cmah-/- mice. Bone appears grey and BMAT is white. D) highlights the 
boundaries of rBMAT and cBMAT within the tibia; rBMAT lies proximal to tibia/fibula junction 
and cBMAT lies distal to tibia/fibula junction (shown by dashed line). E) % total BMAT. F) % 
rBMAT G) % cBMAT. Data is presented as mean ± SD (n = 5).* denotes p<0.05, ** denotes 
p<0.01 compared to WT mice.  
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Table 1 Changes in growth parameters during the study period. Data are presented as mean 
± SD. * denotes p<0.05 compared to WT mice of the same age. 
Mouse type 3 weeks at cull 5 weeks at cull 7 weeks at cull 
 Bodyweight at cull, in g (SD) 
WT 10.03 (1.62) 17.33 (0.98) 21.97 (1.42) 
mdx 9.43 (1.23) 19.07 (2.13) 23.09 (2.90) 
mdx:utrn+/- 8.84 (0.55) 17.36 (1.59) 24.65 (1.62) 
mdx:cmah-/- 8.07 (0.90)* 17.17 (3.13) 24.97 (1.58)* 
 Gain in bodyweight, in g (SD) 
  From 3-5 weeks From 5-7 weeks 
WT - 8.77 (2.24) 3.52 (1.34) 
mdx - 7.93 (3.10) 4.05 (2.25) 
mdx:utrn+/- - 6.57 (3.53) 3.48 (1.30) 
mdx:cmah-/- - 10.61 (1.35) * 4.40 (0.95) 
 Crown-rump length, in cm (SD) 
WT - 7.49 (0.84) 8.84 (0.39) 
mdx - 8.09 (0.23) 8.93 (0.37) 
mdx:utrn+/- - 8.13 (0.38) 8.92 (0.22) 
mdx:cmah-/- - 8.01 (0.30)* 8.55 (0.36) 
 Tail length, in cm (SD) 
WT - 6.86 (0.55) 7.56 (0.26) 
mdx - 6.86 (0.20)      7.42 (0.18) 
mdx:utrn+/- - 6.98 (0.30) 7.74 (0.21) 
mdx:cmah-/- - 6.87 (0.33)     7.25 (0.51) 
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 Table 2 Key trabecular and cortical parameters of tibiae from WT and muscular dystrophy 
mouse models as assessed by CT. Data are presented as mean ± SD (n>6); * denotes 
p<0.05 compared to WT mice. 
Mouse type 3 weeks at cull 5 weeks at cull  7 weeks at cull 
Cortical tissue volume, in mm3 (SD) 
WT 0.45 (0.20)                  0.59 (0.14)               0.71 (0.23)                 
mdx 0.34 (0.16)                  0.72 (0.06)               0.68 (0.20)                 
mdx:utrn+/- 0.45 (0.14)                  0.73 (0.05) 0.51 (0.20)                 
mdx:cmah-/- 0.48 (0.06) 0.69 (0.06) 0.86 (0.08) 
Cortical bone volume, in mm3 (SD) 
WT 0.22 (0.11)                  0.34 (0.09)               0.44 (0.15)                 
mdx 0.15 (0.07)                  0.43 (0.04)               0.44 (0.12)                 
mdx:utrn+/- 0.20 (0.06)                  0.44 (0.02) 0.33 (0.13)                 
mdx:cmah-/- 0.20 (0.03) 0.41 (0.04) 0.56 (0.07) 
Cortical bone fraction (%) (SD) 
WT 46.62 (4.55)                    56.63 (5.57)               61.98 (1.66)                 
mdx 44.56 (3.30)                  59.31 (1.51)               65.30 (2.20)  * 
mdx:utrn+/- 45.76 (1.02))                    59.56 (2.50) 65.50 (2.09)  * 
mdx:cmah-/- 41.46 (4.50) * 60.10 (1.61)  64.64 (2.64)  *             
Trabecular tissue volume, in mm3 (SD) 
WT 1.48 (0.27)                1.91 (0.36)                 2.38 (0.16)                 
mdx 1.24 (0.09)             1.90 (0.15)                 2.15 (0.35)         
mdx:utrn+/- 1.17 (0.09)               1.79 (0.27)  2.37 (0.22)                   
mdx:cmah-/- 1.03 (0.22) *** 1.54 (0.19) 1.84 (0.14) *** 
 Trabecular bone volume, in mm3 (SD) 
WT 0.11 (0.03)                 0.19 (0.05) 0.32 (0.07)                 
mdx 0.08 (0.02)                0.16 (0.04)            0.24 (0.08)                 
mdx:utrn+/- 0.08 (0.01)                 0.14 (0.04)  0.25 (0.07)                   
mdx:cmah-/- 0.08 (0.02) 0.16 (0.03) 0.25 (0.05) 
Trabecular BV/TV % (SD) 
WT 6.78 (0.79)                 9.71 (1.61)                 13.28 (2.34)                 
mdx 6.55 (1.17)                 8.36 (1.55)               11.16 (2.23)                 
mdx:utrn+/- 6.82 (1.10)                 7.83 (1.32)  10.49 (1.90)                   
mdx:cmah-/- 8.30 (1.15) 10.36 (1.88) 13.54 (2.24) 
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 Table 3 Biomechanical properties of tibiae from WT and muscular dystrophy mouse models 
as assessed by 3-point bending. Data are presented as mean ± SD.* denotes p<0.05 
compared to WT mice. 
 
Mouse type 3 weeks at cull 5 weeks at cull  7 weeks at cull 
 
 
Maximum load, in N (SD) 
WT  3.16 (1.68)                 7.42 (3.11)                 6.87 (4.57)                  
mdx  5.33 (8.12)                 5.16 (0.80)  9.30 (2.94)                
mdx:utrn+/- 3.69 (3.76)                 4.49 (0.55)  10.62 (3.01)                
mdx:cmah-/- 1.77 (0.37) 4.47 (1.17)  7.10 (0.92) 
Deflection at max load, in mm (SD) 
WT 1.21 (0.15)                    1.58 (0.66)               1.07 (0.58)                
mdx 1.92 (1.36)                    1.07 (0.51) 1.31 (0.58)                
mdx:utrn+/- 1.14 (0.37)                    1.19 (0.06) 1.61 (0.70)                
mdx:cmah-/- 0.69 (0.31) 0.72 (0.26) * 0.74 (0.28) 
Stiffness, in Nmm (SD) 
WT 19.24 (16.6)                 33.41 (28.41)              37.27 (3.44)               
mdx 11.27 (12.6)                 17.11 (5.21) 25.69 (14.18)               
mdx:utrn+/- 14.84 (14.3)               11.39 (3.21) 25.59 (15.25)               
mdx:cmah-/- 9.09 (5.92) 17.20 (6.87) 19.46 (4.65) 
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 Table 4 Transcripts on qPCR array that were overexpressed in muscular dystrophy models 
compared to WT. Transcripts are included where p-value for change in fold regulation was 
<0.05 Transcripts marked by (A) had an average threshold cycle that was relatively high 
(>30) in the control or the test sample but relatively low (<30) in the other sample. These 
data indicate that the transcript’s expression is relatively low in one sample but readily 
detected in the other sample, suggesting that the actual fold-change value is at least as 
large as the calculated and reported fold-change result. 
Mdx v WT Fold regulation p-value 
Bone morphogenetic protein receptor, type 1 B (Bmpr1b) 2.69 0.04 
Matrix metallopeptidase 10 (Mmp10) 2.03 0.00001 
Mdx:utrn+/- v WT Fold regulation p-value 
Bone morphogenetic protein 6 (Bmp6) 3.6  0.008 
Bone morphogenetic protein receptor, type 1 B (Bmpr1b) 2.29 0.00001 
Fibroblast growth factor 2 (Fgf2) 3.16 0.04 
Integrin alpha M (Itgam) 11.04 0.04 
Matrix metallopeptidase 10 (Mmp10) 2.39 0.000000 
Noggin (Nog) 3.56 0.006 
Tumour necrosis factor (Tnf) 2.38 0.0009 
Mdx:cmah-/- v WT Fold regulation p-value 
Alpha-2-HS-glycoprotein (Ahsg) 3.51 0.04 
Bone morphogenetic protein 2 (Bmp2) 3.24 0.02 
Bone morphogenetic protein receptor, type 1 B (Bmpr1b) 3.63 0.000001 
Colony stimulating factor 3, granulocyte (Csf3) 4.05 0.000000 
Epidermal growth factor (Egf) 4.68 0.05 
Intercellular adhesion molecule 1 (Icam1) 6.18 0.01 
Insulin-like growth factor 1 (Igf1) 30.58 (A) 0.01 
Insulin-like growth factor 1 receptor (Igf1r) 9.98 0.05 
Indian hedgehog (Ihh) 4.08 0.000000 
Integrin alpha 2b (Itga2b) 4.19 0.02 
Integrin alpha 3 (Itga3) 4.85 0.003 
Matrix metallopeptidase 10 (Mmp10) 3.75 0.000000 
Matrix metallopeptidase 8 (Mmp8) 7.64 0.005 
Noggin (Nog) 5.69 0.0008 
SRY-box containing gene 9 (Sox9) 6.18 0.02 
Tumour necrosis factor (Tnf) 4.11 0.01 
Vascular cell adhesion molecule 1 (Vcam1) 4.03 0.02 
Vascular endothelial growth factor A (Vegfa) 32.39 (A) 0.002 
Vascular endothelial growth factor B Vegfb 7.82 0.04 
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Table S1. Cortical bone parameters of tibiae from WT and muscular dystrophy mouse models as 
assessed by µCT. Data are presented as mean ± SD (n>6); * denotes p<0.05 compared to WT mice. 
Mouse type 3 weeks at cull 5 weeks at cull 7 weeks at cull 
 Cortical tissue area, mm2 (SD) 
WT 0.62 (0.09) 0.71 (0.08) 0.94 (0.06) 
mdx 0.56 (0.05) 0.81 (0.07) 0.92 (0.10) 
mdx:utr+/- 0.54 (0.06) 0.81 (0.05) 0.97 (0.08) 
mdx:cmah-/- 0.54 (0.07) 0.76 (0.06) 0.96 (0.08) 
Cortical bone area, mm2 (SD) 
WT 0.29 (0.07) 0.41 (0.07) 0.58 (0.07) 
mdx 0.25 (0.03) 0.48 (0.05) 0.60 (0.07) 
mdx:utr+/- 0.25 (0.03) 0.49 (0.02) 0.63 (0.05) 
mdx:cmah-/- 0.22 (0.03) * 0.46 (0.05) 0.62 (0.07) 
Periosteal perimeter, in mm (SD) 
WT 3.01 (0.22) 3.16 (0.21) 3.74 (0.11) 
mdx 2.85 (0.13) 3.42 (0.16) 3.69 (0.22) 
mdx:utr+/- 2.81 (0.18) 3.45 (0.10) 3.80 (0.16) 
mdx:cmah-/- 2.78 (0.20) 3.38 (0.19) 3.78 (0.17) 
Endosteal perimeter, in mm (SD) 
WT 2.20 (0.11) 2.09 (0.09) 2.33 (0.09) 
mdx 2.19 (0.11) 2.21 (0.09) 2.21 (0.17) 
mdx:utr+/- 2.08 (0.09) 2.19 (0.12) 2.23 (0.12) 
mdx:cmah-/- 2.15 (0.19) 2.09 (0.09) 2.22 (0.07) 
Cortical thickness, in mm (SD) 
WT 0.50 (0.08) 0.52 (0.06) 0.51 (0.08) 
mdx 0.46 (0.08) 0.55 (0.02) 0.49 (0.07) 
mdx:utr+/- 0.48 (0.07) 0.55 (0.03) 0.43 (0.06) 
mdx:cmah-/- 0.54 (0.04) 0.54 (0.02) 0.55 (0.02) 
Mean polar moment of inertia, in mm4 (SD) 
WT 0.05 (0.02) 0.06 (0.02)  0.12 (0.02) 
mdx 0.04 (0.01) 0.09 (0.01)  0.12 (0.03) 
mdx:utr+/- 0.03 (0.01) 0.09 (0.01)  0.14 (0.02)  
mdx:cmah-/- 0.03 (0.01) 0.08 (0.01)  0.13 (0.03)  
Mean eccentricity (SD) 
WT 0.57 (0.10) 0.55 (0.15) 0.52 (0.09) 
mdx 0.47 (0.11) 0.60  (0.07) 0.59 (0.11) 
mdx:utr+/- 0.61 (0.10) 0.63 (0.03) 0.56 (0.07) 
mdx:cmah-/- 0.58 (0.10) 0.53 (0.06) 0.57 (0.11) 
Disease Models & Mechanisms: doi:10.1242/dmm.040659: Supplementary information
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Mouse type 3 weeks at cull 5 weeks at cull 7 weeks at cull 
Trabecular thickness, in mm (SD) 
WT 0.03 (0.003)  0.04 (0.003)  0.04 (0.001)  
mdx 0.03 (0.002)  0.04 (0.001)  0.04 (0.002)  
mdx:utr+/- 0.03 (0.002)  0.04 (0.002) 0.04 (0.001)  
mdx: cmah-/- 0.03 (0.001) 0.04 (0.002) 0.05 (0.003) * 
Trabecular separation, in mm (SD) 
WT 0.30 (0.05) 0.24 (0.05) 0.18 (0.02) 
mdx 0.37 (0.07) 0.26 (0.04) 0.21 (0.02) 
mdx:utr+/- 0.36 (0.03) 0.30 (0.06) 0.20 (0.02) 
mdx: cmah-/- 0.29 (0.46) 0.23 (0.02) 0.19 (0.01) 
Trabecular number, in 1/mm (SD) 
WT 2.04 (0.15) 2.64 (0.43) 3.10 (0.43) 
mdx 2.08 (0.42) 2.17 (0.39) 2.67 (0.44) 
mdx:utr+/- 2.06 (0.38) 1.96 (0.29) * 2.62 (0.45) 
mdx: cmah-/- 2.66 (0.45) * 2.54 (0.35) 2.96 (0.41) 
Structural Model Index (SD) 
WT 2.32 (0.08) 2.19 (0.10) 2.14 (0.10) 
mdx 2.20 (0.10) 2.31 (0.11) 2.18 (0.07) 
mdx:utr+/- 2.15 (0.10) *  2.31 (0.06) 2.21 (0.14) 
mdx: cmah-/- 2.19 (0.09) 2.15 (0.13) 2.07 (0.19) 
Connectivity (SD) 
WT 618.9 (121.4)  867.3 (221.4)      1042.6 (195.2) 
mdx 516.5 (147.2) 702.6 (136.8)       818.1 (207.2)      
mdx:utr+/- 429.6 (108.8) 554.4 (78.1) * 897.5 (177.2)      
mdx: cmah-/- 561.8 (72.5) 527.5 (107.8) ** 723.3 (85.0)*** 
Table S2. Trabecular bone parameters of tibiae from WT and muscular dystrophy mouse models as 
assessed by µCT. Data are presented as mean ± SD (n>6); * denotes p<0.05 compared to WT mice. 
Mouse type Tibiae length, in mm (SD) 
3 weeks at cull 5 weeks at cull 7 weeks at cull 
WT 13.02 (0.96) 14.93 (0.18) 16.07 (0.17) 
mdx 12.07(0.49) 14.82 (0.59) 16.10 (0.35) 
mdx:utr+/- 12.42 (0.12) 14.84 (0.84) 16.27(0.30) 
mdx:cmah-/- 12.45 (0.39) 14.99 (0.53) 16.60 (0.42) 
Table S3. Tibial length from WT and muscular dystrophy mouse models as assessed by µCT. Data are 
presented as mean ± SD (n>6).
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Figure S1.  The width of the total growth plate and the individual proliferating and hypertrophic zones 
were similar at A) 3 weeks of age, and B) 7 weeks of age. C) The percentage of proliferating growth 
plate chondrocytes was similar in 3-week-old muscular dystrophy and WT mice. Data is presented as 
mean ± SD (n > 6).  D) The growth of cultured embryonic (E18) metatarsals from muscular dystrophy 
and WT mice were similar. Data is presented as mean ± SD (n = 12 metatarsals).   
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